A Phase 3 interventional study of Letrozole and Tamoxifen in Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in 2 countries. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-03-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.
Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 38th largest by enrollment of the 159 interventional ones that give a count, is one of 11 that started in 2005, is one of 41 in phase 3, and was the 16th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fujian Cancer Hospital · Sites in China
Ages 18+ · Women only
Hebei Medical University Fourth Hospital · Sites in China
Ages 18–75 · Women only
Celcuity Inc · Sites in United States, Argentina, Australia and 22 more countries
Ages 18+
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
Mridula George, MD · Sites in United States
Ages 60+ · Women only
By country, each count listing its studies:
Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 50 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 83 · Phase 3 45 · Phase 4 17
First in 1998; this study’s year is marked. 11 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 263 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 95 across the 159 interventional studies. Of the 109 that completed or were terminated, 44 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 162 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 46th largest by enrollment of the 155 interventional ones that give a count, is one of 10 that started in 2005, is one of 45 in phase 3, and was the 11th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
8 of the studies testing letrozole in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT04486911Shengjing HospitalPyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial | 2026-12-01 |
| NCT05286437National Cancer Centre, SingaporePhase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole | 2026-12-31 |
| NCT07492394Hebei Medical University Fourth HospitalDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer | 2026-12-31 |
| NCT02562118National University Hospital, SingaporeNeoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 162 studies testing letrozole in Breast Neoplasms, from their registry updates:
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis.
This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal women with resected, receptor positive early breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.5 mg once daily (q.d.)orally for 5 years
Drug: Letrozole
20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.
Drug: Letrozole · Drug: Tamoxifen
Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)
Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader.
Time frame: Baseline, 24 months
Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine
Lumbar spine (L2-L4)BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader.
Time frame: Baseline, 60 months
Percent Change From Baseline of Bone Mineral Density (BMD) of Total Hip
Total hip BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. All DXA scans were evaluated by a central reader.
Time frame: Baseline, 60 months
Median Percent Change From Baseline of Serum Markers of Bone Turnover
Bone turnover markers (fasting serum procollagen-I extension peptide \[P1NP\], C-telopeptide \[CTX\], skeletal bone-specific alkaline phosphatase \[BSAP, N-telopeptide \[NTX\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. The analysis of bone markers was based on analysis of variance of the regression slopes calculated for each individual patient and each bone marker over time. In the following summary, only the median treatment group percent change from baseline (and range) at 5 years is presented for each bone marker.
Time frame: Baseline, 60 months
Percentage Change From Baseline in Serum Lipids at 5 Years
Serum lipid profile (fasting serum cholesterol \[total, HDL and calculated LDL\], triglycerides, and lipoprotein \[a\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. The analysis of serum lipids was on the treatment group median percent change from baseline (and range) at 5 years.
Time frame: Baseline, 60 months
Number of Participants With Clinically Relevant Changes From Baseline in Cholesterol
Serum lipid profile (fasting serum cholesterol \[total, HDL and calculated LDL\], triglycerides, and lipoprotein \[a\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. Numbers are not additive, as patients could be included in multiple rows.
Time frame: Baseline, 60 months
Time to Disease Recurrence or Death
Disease-free survival was defined as the interval between randomization and earliest confirmed event of loco-regional recurrence, distant metastases, invasive contralateral breast cancer, or death from any cause.
Time frame: 60 months
Time to Overall Survival Events
Overall survival was measured from date of randomization to date of death.
Time frame: 60 Months
| Milestone | Letrozole | Tam-Let |
|---|---|---|
| Started | 133 | 130 |
| Completed | 89 | 81 |
| Not completed | 44 | 49 |
| Withdrew: Adverse event | 24 | 33 |
| Withdrew: Disease progression | 14 | 9 |
| Withdrew: New therapy for 2nd non-breast prim canc | 1 | 0 |
| Withdrew: Administrative problems | 2 | 1 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Protocol violation | 0 | 1 |
Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader.
| Percent Change | Letrozole | Tam-Let |
|---|---|---|
| Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4) | -4.63 (-14.21 to 4.32) | 0.37 (-6.98 to 15.21) |
Lumbar spine (L2-L4)BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader.
| Percent change | Letrozole | Tam-Let |
|---|---|---|
| Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine | -5.66 (-15.06 to 5.11) | -3.3 (-13.48 to 4.92) |
Total hip BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. All DXA scans were evaluated by a central reader.
| Percent Change | Letrozole | Tam-Let |
|---|---|---|
| Percent Change From Baseline of Bone Mineral Density (BMD) of Total Hip | -5.77 (-22.53 to 12.53) | -3.98 (-13.6 to 5.57) |
Bone turnover markers (fasting serum procollagen-I extension peptide \[P1NP\], C-telopeptide \[CTX\], skeletal bone-specific alkaline phosphatase \[BSAP, N-telopeptide \[NTX\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. The analysis of bone markers was based on analysis of variance of the regression slopes calculated for each individual patient and each bone marker over time. In the following summary, only the median treatment group percent change from baseline (and range) at 5 years is presented for each bone marker.
| Percent Change | Letrozole | Tam-Let |
|---|---|---|
| Procollagen-I (PINP) (n=86, 78) | -14.15 (-78.5 to 177.8) | -0.5 (-84.8 to 200) |
| Bone Specific alkaline Phosphatase (n=87,78) | 16.2 (-53.6 to 192.6) | 19.15 (-58.00 to 237.8) |
| C-telopeptide (CTX) (n=88, 78) | -12.05 (-80.9 to 130.6) | 4.55 (-81.2 to 236.8) |
| N-telopeptide (NTX) (n=-88, 77) | -53.05 (-86.3 to 20.2) | -50.7 (-100 to 39) |
Serum lipid profile (fasting serum cholesterol \[total, HDL and calculated LDL\], triglycerides, and lipoprotein \[a\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. The analysis of serum lipids was on the treatment group median percent change from baseline (and range) at 5 years.
| Percent Change | Letrozole | Tam-Let |
|---|---|---|
| Total Cholesterol (n=91, 82) | -7.3 ± 17.64 | -2.45 ± 16.63 |
| LDL Cholesterol (n=91, 82) | -12.7 ± 24.947 | -11.05 ± 23.958 |
| HDL Cholesterol (n=91, 82) | 8.7 ± 16.388 | 8.9 ± -38.5 |
Serum lipid profile (fasting serum cholesterol \[total, HDL and calculated LDL\], triglycerides, and lipoprotein \[a\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. Numbers are not additive, as patients could be included in multiple rows.
| Participants | Letrozole | Tam-Let |
|---|---|---|
| Patients with one or more change | 30 | 21 |
| ≥8 mmol/L total (T) cholesterol | 7 | 5 |
| ≥7 mmol/L T.choles. & ≥1 risk for cardiac disease | 18 | 12 |
| ≥6 mmol/L T. choles. & ≥2 risk for cardiac disease | 11 | 9 |
Disease-free survival was defined as the interval between randomization and earliest confirmed event of loco-regional recurrence, distant metastases, invasive contralateral breast cancer, or death from any cause.
| Days | Letrozole | Tam-Let |
|---|---|---|
| Time to Disease Recurrence or Death | NA (NA to NA) | NA (NA to NA) |
Overall survival was measured from date of randomization to date of death.
| days | Letrozole | Tam-Let |
|---|---|---|
| Time to Overall Survival Events | NA (NA to NA) | NA (NA to NA) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Letrozole | — | 50/133 (37.6%) | 113/133 (85%) |
| Tam-Let | — | 41/130 (31.5%) | 110/130 (84.6%) |
| Event | Letrozole | Tam-Let |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 5/133 | 4/130 |
| PneumoniaInfections and infestations | 4/133 | 1/130 |
| DiverticulitisInfections and infestations | 3/133 | 0/130 |
| Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/133 | 0/130 |
| Acute myocardial infarctionCardiac disorders | 0/133 | 2/130 |
| Atrial fibrillationCardiac disorders | 2/133 | 2/130 |
| Breast infectionInfections and infestations | 0/133 | 2/130 |
| ErysipelasInfections and infestations | 1/133 | 2/130 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/133 | 2/130 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/133 | 2/130 |
| Event | Letrozole | Tam-Let |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 44/133 | 43/130 |
| Back painMusculoskeletal and connective tissue disorders | 14/133 | 25/130 |
| HypertensionVascular disorders | 25/133 | 17/130 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 23/133 | 21/130 |
| OsteoporosisMusculoskeletal and connective tissue disorders | 21/133 | 8/130 |
| Hot flushVascular disorders | 13/133 | 18/130 |
| Oedema peripheralGeneral disorders | 17/133 | 15/130 |
| Bone painMusculoskeletal and connective tissue disorders | 16/133 | 10/130 |
| FatigueGeneral disorders | 7/133 | 15/130 |
| OsteopeniaMusculoskeletal and connective tissue disorders | 15/133 | 12/130 |
| Age, Continuous(years) | Letrozole | Tam-Let | Total |
|---|---|---|---|
| Mean | 61.4 ± 6.1 | 61.8 ± 6.2 | 61.6 ± 6.2 |
| Sex: Female, Male(Participants) | Letrozole | Tam-Let | Total |
|---|---|---|---|
| Female | 133 | 130 | 263 |
| Male | 0 | 0 | 0 |
The record gives a start of Apr 2005, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letrozole